Exclusive Summary

• First-in-Class Modality & Mechanism: UB691 is a globally pioneering long-acting, lung-targeted CTGF siRNA drug that effectively silences all four CTGF isoforms, presenting superior pathway suppression over conventional monoclonal antibodies.
• Breakthrough Administration & Supreme Patient Compliance: Utilizing a proprietary pulmonary siRNA delivery platform for nebulized inhalation, it directly targets the lesions and offers a paradigm-shifting once-every-two-months (Q2M) dosing potential, drastically relieving the dosing burden.
• Directly Addressing Critical IPF Unmet Needs: Addressing a fatal disease with merely 3-5 years of median survival and no fibrotic-halting therapies, preclinical mouse models prove UB691 exerts substantial anti-fibrotic and anti-inflammatory efficacy as both monotherapy and combination therapy.
• Broad Blockbuster & Out-Licensing Value: Currently in the indispensable IND-enabling phase, its combination of a novel validated target, advanced siRNA modality, and proprietary delivery technology stands as a highly profitable License-out asset for MNCs building strategic RNAi and respiratory disease pipelines.

Asset Materials

Contact Us for Full Materials